Covance-BML lab to expand in Japan

Thursday, April 26, 2012

CRO Covance of Princeton, N.J., and BML, a Japanese laboratory testing company, will expand the Covance-BML Clinical Trial Laboratory (CB Trial Lab) in Kawagoe City, Saitama Prefecture, to enhance the capacity and capabilities in the region. The companies, which opened the lab together in 2010 as part of a five-year agreement, will launch several new expansion-related services this month.

[Read More]

Icon boosts its presence in Asia with acquisition of Chinese CRO BeijingWits Medical Consulting

Monday, December 19, 2011

Now that many mid-tier CROs have been acquired by either equity investment firms or other CROs and the trend has slowed, a new form of consolidation is emerging. Robust CROs are rounding out their offerings with small but strategic acquisitions to make them bigger, stronger and more complete. The ultimate goal: to continue winning lucrative strategic outsourcing agreements from sponsors.  

[Read More]

CROs form Asia CRO Alliance

Thursday, December 15, 2011

Six Asian CROs have founded the Asia CRO Alliance (ACA) to combine regional expertise and provide integrated services across Asia. According to the ACA web site, it is the first and only alliance of niche, regional CROs in Asia to partner to enhance clinical research inAsia.

[Read More]

Mochida inks license agreement with Merck

Tuesday, December 13, 2011

Mochida Pharmaceutical has entered into a license agreement with Merck, through a subsidiary, relating to a portfolio of drug candidates invented by Mochida for the potential treatment for type-2 diabetes. Under the terms of the agreement, Merck has been granted a worldwide exclusive license to develop, manufacture, use and sell the potential drug candidates. Mochida will receive from Merck an upfront payment and potential development milestone payments, as well as royalties on the sales of any products derived from the collaboration. Mochida has retained an option to co-develop and co-market any products in Japan.

[Read More]

Merck establishes R&D headquarters in China

Tuesday, December 6, 2011

Merck, known as MSD outside the United States and Canada, has established an Asia research & development headquarters for innovative drug discovery and development located in Beijing, China. The new facility is part of a $1.5 billion commitment the company has made to invest in R&D in China over the next five years.

[Read More]